Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
LABP Stock Summary
Top 10 Correlated ETFs
LABP
In the News

3 Top Biotech Penny Stocks Under $3 To Watch Right Now
Biotech penny stocks to watch right now. The post 3 Top Biotech Penny Stocks Under $3 To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Biotech Stocks Set to Outpace Q1 Earnings Estimates
Let us take a look at some drug/biotech stocks, ANGN, APLT, BOLT, IKNA and LABP, which are poised to beat on first-quarter earnings.

Landos Biopharma, Inc.'s (LABP) CEO Tim Mayleben on Q3 2021 Results - Earnings Call Transcript
Landos Biopharma, Inc.'s (LABP) CEO Tim Mayleben on Q3 2021 Results - Earnings Call Transcript

Should You Buy Landos Biopharma (LABP) Ahead of Earnings?
Landos Biopharma (LABP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Systemic Lupus Erythematosus
Phase 1 trial initiation expected before yearend with topline results in 1H 2022

Landos Biopharma Announces Publication in Scientific Reports of Novel Preclinical Findings Demonstrating Omilancor's Therapeutic Potential in Models of Psoriasis and Further Validating the LANCL2 Mechanism
BLACKSBURG, Va., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to discover and develop novel therapeutics for patients with autoimmune diseases, today announced the publication of a peer-reviewed article titled “First-in-class topical therapeutic omilancor ameliorates disease severity and inflammation through activation of the LANCL2 pathway in psoriasis” in Scientific Reports. The peer-reviewed publication demonstrates omilancor's therapeutic efficacy in animal models of psoriasis.

Landos Biopharma to Participate in Two Upcoming Investor Conferences in September
BLACKSBURG, Va., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel oral therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos will participate in two upcoming virtual investor conferences in September.

Landos Biopharma Announces Research Collaboration into the NLRX1 Pathway in Multiple Sclerosis with Johns Hopkins University School of Medicine
BLACKSBURG, Va., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel oral therapeutics for patients with autoimmune diseases, today announced that it has entered into a research collaboration with Peter Calabresi, M.D., Director of the Multiple Sclerosis Center and Professor of Neurology at Johns Hopkins University (JHU) School of Medicine. This research funded by the National Institutes of Health (NIH) will focus on further validating the NLRX1 immunometabolic pathway in Multiple Sclerosis (MS).

Landos Biopharma to Participate in Upcoming Investor Events
BLACKSBURG, Va., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel oral therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos and additional management team members will participate in the following investor events in August.

Landos Biopharma to Present at the Raymond James Virtual Human Health Innovation Conference
BLACKSBURG, Va., June 14, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE Advanced A.I. platform to discover and develop novel oral therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos, will present at the upcoming Raymond James Virtual Human Health Innovation Conference on Monday, June 21, 2021 at 2:00 PM EDT.
LABP Financial details
LABP Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0.46 | |
Net income per share | -0.26 | -0.58 | -0.77 | -0.98 | |
Operating cash flow per share | -0.3 | -0.43 | -0.59 | -0.69 | |
Free cash flow per share | -0.3 | -0.43 | -0.59 | -0.7 | |
Cash per share | 0.02 | 2.16 | 0.72 | 2.32 | |
Book value per share | 0.04 | -1.11 | -1.38 | 1.95 | |
Tangible book value per share | 0.04 | -1.11 | 1.14 | 1.95 | |
Share holders equity per share | 0.04 | -1.11 | -1.38 | 1.95 | |
Interest debt per share | 0 | 0.01 | 0 | 0.01 | |
Market cap | 277.24M | 277.24M | 469.96M | 187.98M | |
Enterprise value | 276.88M | 267.43M | 467.54M | 179.68M | |
P/E ratio | -45.87 | -20.59 | -15.59 | -4.89 | |
Price to sales ratio | 0 | 0 | 0 | 10.44 | |
POCF ratio | -40.2 | -28.08 | -20.47 | -6.95 | |
PFCF ratio | -39.95 | -27.64 | -20.31 | -6.84 | |
P/B Ratio | 277.24 | -10.84 | -8.7 | 2.46 | |
PTB ratio | 277.24 | -10.84 | -8.7 | 2.46 | |
EV to sales | 0 | 0 | 0 | 9.98 | |
Enterprise value over EBITDA | -46.46 | -20.48 | -15.58 | -4.75 | |
EV to operating cash flow | -40.15 | -27.08 | -20.36 | -6.64 | |
EV to free cash flow | -39.9 | -26.66 | -20.2 | -6.53 | |
Earnings yield | -0.02 | -0.05 | -0.06 | -0.2 | |
Free cash flow yield | -0.03 | -0.04 | -0.05 | -0.15 | |
Debt to equity | 1.8 | -2.97 | -0.21 | 0.22 | |
Debt to assets | 0.64 | 1.51 | 0.2 | 0.18 | |
Net debt to EBITDA | 0.06 | 0.75 | 0.08 | 0.22 | |
Current ratio | 1.39 | 16.56 | 2.71 | 5.55 | |
Interest coverage | -1.98K | -43.72 | 0 | -94.21 | |
Income quality | 1.14 | 0.73 | 0.76 | 0.7 | |
Dividend Yield | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0.85 | |
Research and developement to revenue | 0 | 0 | 0 | 2.31 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0.02 | 0.01 | 0.02 | |
Capex to revenue | 0 | 0 | 0 | -0.02 | |
Capex to depreciation | -0.54 | -1.53 | -1.32 | -2.24 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0.23 | |
Graham number | 0.5 | 3.81 | 4.89 | 6.56 | |
ROIC | -20.57 | -0.46 | -0.72 | -0.61 | |
Return on tangible assets | -2.16 | -0.27 | -0.54 | -0.41 | |
Graham Net | 0.01 | -1.13 | 0.43 | 1.9 | |
Working capital | 696K | 47.08M | 18.85M | 75.54M | |
Tangible asset value | 1000K | -25.58M | 44.74M | 76.27M | |
Net current asset value | 696K | -25.95M | 18.58M | 75.54M | |
Invested capital | 0 | 0 | 0 | 0 | |
Average receivables | 0 | 1.05M | 500 | 0 | |
Average payables | 0 | 1.87M | 5.33M | 10.76M | |
Average inventory | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | |
ROE | -6.04 | 0.53 | 0.56 | -0.5 | |
Capex per share | 0 | -0.01 | 0 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.32 | -0.6 | -0.37 | -0.28 | -0.2 | |
Operating cash flow per share | -0.3 | -0.36 | -0.41 | -0.45 | -0.19 | |
Free cash flow per share | -0.3 | -0.36 | -0.41 | -0.45 | -0.19 | |
Cash per share | 2.57 | 2.7 | 1.83 | 1.38 | 1.19 | |
Book value per share | 2.35 | 2.27 | 1.54 | 1.28 | 1.09 | |
Tangible book value per share | 2.35 | 2.27 | 1.54 | 1.28 | 1.09 | |
Share holders equity per share | 2.35 | 2.27 | 1.54 | 1.28 | 1.09 | |
Interest debt per share | 0 | 0.01 | 0 | 0 | 0 | |
Market cap | 583.45M | 161.47M | 59.38M | 29.3M | 26.17M | |
Enterprise value | 565.55M | 153.16M | 48.11M | 10.06M | -2.71M | |
P/E ratio | -11.57 | -2.01 | -1 | -0.65 | -0.83 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -49.26 | -13.39 | -3.6 | -1.63 | -3.46 | |
PFCF ratio | -48.19 | -13.43 | -3.6 | -1.63 | -3.46 | |
P/B Ratio | 6.21 | 2.12 | 0.96 | 0.57 | 0.59 | |
PTB ratio | 6.21 | 2.12 | 0.96 | 0.57 | 0.59 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -45.04 | -7.77 | -3.32 | -0.91 | 0.34 | |
EV to operating cash flow | -47.75 | -12.7 | -2.92 | -0.56 | 0.36 | |
EV to free cash flow | -46.71 | -12.74 | -2.91 | -0.56 | 0.36 | |
Earnings yield | -0.02 | -0.12 | -0.25 | -0.39 | -0.3 | |
Free cash flow yield | -0.02 | -0.07 | -0.28 | -0.61 | -0.29 | |
Debt to equity | 0.12 | 0.22 | 0.25 | 0.13 | 0.12 | |
Debt to assets | 0.11 | 0.18 | 0.2 | 0.11 | 0.11 | |
Net debt to EBITDA | 1.43 | 0.42 | 0.78 | 1.74 | 3.66 | |
Current ratio | 9.4 | 5.55 | 4.99 | 8.92 | 9.04 | |
Interest coverage | 0 | -63.74 | 0 | 0 | 0 | |
Income quality | 0.94 | 0.6 | 1.11 | 1.59 | 0.96 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.02 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -5.5 | 0 | -0.02 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 4.08 | 5.52 | 3.58 | 2.84 | 2.2 | |
ROIC | -0.21 | -0.32 | -0.33 | -0.76 | 0.68 | |
Return on tangible assets | -0.12 | -0.22 | -0.19 | -0.19 | -0.16 | |
Graham Net | 2.29 | 2.21 | 1.45 | 1.22 | 1.06 | |
Working capital | 93.22M | 75.54M | 61.85M | 51.53M | 44.01M | |
Tangible asset value | 93.92M | 76.27M | 62.1M | 51.53M | 44.01M | |
Net current asset value | 93.14M | 75.54M | 61.85M | 51.53M | 44.01M | |
Invested capital | 0 | 0 | 0 | 0 | 0 | |
Average receivables | 1000 | 0 | 0 | 0 | 0 | |
Average payables | 10.4M | 11.51M | 11.36M | 7.26M | 3.96M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.13 | -0.26 | -0.24 | -0.22 | -0.18 | |
Capex per share | -0.01 | 0 | 0 | 0 | 0 |
LABP Frequently Asked Questions
What is Landos Biopharma, Inc. stock symbol ?
Landos Biopharma, Inc. is a US stock , located in Blacksburg of Va and trading under the symbol LABP
What is Landos Biopharma, Inc. stock quote today ?
Landos Biopharma, Inc. stock price is $0.265 today.
Is Landos Biopharma, Inc. stock public?
Yes, Landos Biopharma, Inc. is a publicly traded company.